Fos/1 is a transcriptional target of c-Fos during osteoclast differentiation

Nature Genetics

Volumn 24, Issue 2, 2000, Pages 184-187

  Matsuo, Koichi ^a   Owens, Jane M ^b   Tonko, Martin ^a   Elliott, Candace ^a   Chambers, Timothy J ^b   Wagner, Erwin F ^a  

^a RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN C FOS; CARRIER PROTEIN; DNA BINDING PROTEIN; FOSL2 PROTEIN, MOUSE; MEMBRANE PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11A PROTEIN, MOUSE; TNFSF11 PROTEIN, MOUSE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FRA 1; TRANSCRIPTION FACTOR FRA 2;

ALBERS SCHOENBERG DISEASE; ANIMAL EXPERIMENT; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CELL TRANSFORMATION; GENE TRANSFER; MALE; MOUSE; NONHUMAN; ONCOGENE C FOS; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRANSGENE; ANIMAL; CELL CULTURE; CYTOLOGY; DIMERIZATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MOUSE MUTANT; ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPLEEN; TRANSGENIC MOUSE;

ANIMALS; CARRIER PROTEINS; CELL DIFFERENTIATION; CELLS, CULTURED; DIMERIZATION; DNA-BINDING PROTEINS; FOS-RELATED ANTIGEN-2; GENES, FOS; MEMBRANE GLYCOPROTEINS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; OSTEOCLASTS; PROTO-ONCOGENE PROTEINS C-FOS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SPLEEN; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 0033621698     PISSN: 10614036     EISSN: None     Source Type: Journal    
DOI: 10.1038/72855     Document Type: Article

References (30)

1. Wang, Z.Q. et al. Bone and haematopoietic defects in mice lacking c-fos. Nature 360, 741-745 (1992).
2. Johnson, R.S., Spiegelman, B.M. & Papaioannou, V. Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell 71, 577-586 (1992).
3. Grigoriadis, A.E. et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266, 443-448 (1994).
4. Wisdon, R. & Verma, I.M. Transformation by Fos proteins requires a C-terminal transactivation domain. Mol. Cell. Biol. 13, 7429-7438 (1993).
5. Jooss, K.U., Funk, M. & Müller, R. An autonomous N-terminal transactivation domain in Fos protein plays a crucial role in transformation. EMBO J. 13, 1467-1475 (1994).
6. Funk, M., Poensgen, B., Graulich, W., Jerome, V. & Müller, R. A novel, transformation-relevant activation domain in Fos proteins. Mol. Cell. Biol. 17, 537-544 (1997).
7. Bergers, G., Graninger, P., Braselmann, S., Wrighton, C. & Busslinger, M. Transcriptional activation of the fra-1 gene by AP-1 is mediated by regulatory sequences in the first intron. Mol. Cell. Biol. 15, 3748-3758 (1995).
8. Wong, B.R. et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J. Exp. Med. 186, 2075-2080 (1997).
9. Anderson, D.M. et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390, 175-179 (1997).
10. Yasuda, H. et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl Acad. Sci. USA 95, 3597-3602 (1998).
11. Lacey, D.L. et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165-176 (1998).
12. Kustikova, O. et al. Fra-1 induces morphological transformation and increases in vitro invasiveness and motility of epithelioid adenocarcinoma cells. Mol. Cell. Biol. 18, 7095-7105 (1998).
13. Grigoriadis, A.E., Schellander, K., Wang, Z.Q. & Wagner, E.F. Osteoblasts are target cells for transformation in c-fos transgenic mice. J. Cell Biol. 122, 685-701 (1993).
14. Sutherland, J.A., Cook, A., Bannister, A.J. & Kouzarides, T. Conserved motifs in Fos and Jun define a new class of activation domain. Genes Dev. 6, 1810-1819 (1992).
15. Metz, R. et al. c-Fos-induced activation of a TATA-box-containing promoter involves direct contact with TATA-box-binding protein. Mol. Cell. Biol. 14, 6021-6029 (1994).
16. Metz, R., Kouzarides, T. & Bravo, R. A C-terminal domain in FosB, absent in FosB/SF and Fra-1, which is able to interact with the TATA binding protein, is required for altered cell growth. EMBO J. 13, 3832-3842 (1994).
17. Wisdom, R., Yen, J., Rashid, D. & Verma, I.M. Transformation by FosB requires a trans-activation domain missing in FosB2 that can be substituted by heterologous activation domains. Genes Dev. 6, 667-675 (1992).
18. Oliviero, S., Robinson, G.S., Struhl, K. & Spiegelman, B.M. Yeast GCN4 as a probe for oncogenesis by AP-1 transcription factors: transcriptional activation through AP-1 sites is not sufficient for cellular transformation. Genes Dev. 6, 1799-1809 (1992).
19. Wrighton, C. & Busslinger, M, Direct transcriptional stimulation of the ornithine decarboxylase gene by Fos in PC12 cells but not in fibroblasts. Mol. Cell. Biol. 13, 4657-4669 (1993).
20. Owens, J.M., Matsuo, K., Nicholson, G.C., Wagner, E.F. & Chambers, T.J. Fra-1 potentiates osteoclastic differentiation in osteoclast-macrophage precursor cell lines. J. Cell. Physiol. 179, 170-178 (1999).
21. Hsu, H. et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl Acad. Sci. USA 96, 3540-3545 (1999).
22. Russell, R.G.G. & Rogers, M.J. Bisphosphonates: from the laboratory to the clinic and back again. Bone 25, 97-106 (1999).
23. Schreiber, M. et al. Structure and chromosomal assignment of the mouse fra-1 gene, and its exclusion as a candidate gene for oc (osteosclerosis). Oncogene 15, 1171-1178 (1997).
24. Kong, Y.Y. et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397, 315-323 (1999).
25. Dougall, W.C. et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 13, 2412-2424 (1999).
26. Morgenstern, J.P. & Land, H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res. 18, 3587-3596 (1990).
27. Chambers, T.J., Owens, J.M., Hattersley, G., Jat, P.S. & Noble, M.D. Generation of osteoclast-inductive and osteoclastogenic cell lines from the H-2KbtsA58 transgenic mouse. Proc. Natl Acad. Sci. USA 90, 5578-5582 (1993).
28. Livak, K.J., Flood, S.J., Marmaro, J., Giusti, W. & Deetz, K. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Methods Appl. 4, 357-362 (1995).
29. Brown, H.J., Sutherland, J.A., Cook, A., Bannister, A.J. & Kouzarides, T. An inhibitor domain in c-Fos regulates activation domains containing the HOB1 motif. EMBO J. 14, 124-131 (1995).
30. Gius, D. et al. Transcriptional activation and repression by Fos are independent functions: the C terminus represses immediate-early gene expression via CArG elements. Mol. Cell. Biol. 10, 4243-4255 (1990).